Literature DB >> 12054732

Synthesis, aggregation, neurotoxicity, and secondary structure of various A beta 1-42 mutants of familial Alzheimer's disease at positions 21-23.

Kazuma Murakami1, Kazuhiro Irie, Akira Morimoto, Hajime Ohigashi, Mayumi Shindo, Masaya Nagao, Takahiko Shimizu, Takuji Shirasawa.   

Abstract

Cerebral amyloid angiopathy (CAA) due to amyloid beta (A beta) deposition is a key pathological feature of Alzheimer's disease (AD), especially in some form of familial Alzheimer's disease (FAD) including hereditary cerebral hemorrhage with amyloidosis-Dutch type. A beta mainly consists of 40- and 42-mer peptides (Abeta 1-40 and A beta 1-42), which accumulate in senile plaques of AD brains and show neurotoxicity for cultured nerve cells. We synthesized all variant forms of A beta 1-42 associated with reported FAD, such as A21G (Flemish), E22Q (Dutch), E22K (Italian), E22G (Arctic), and D23N (Iowa) along with three potential mutants by one point missense mutation (E22A, E22D, and E22V) in a highly pure form, and examined their ability to aggregate and their neurotoxicity in PC12 cells. The mutants at positions 22 and 23 showed potent aggregative ability and neurotoxicity whereas the potential mutants did not, indicating that A beta 1-42 mutants at positions 22 and 23 play a critical role in FAD of Dutch-, Italian-, Arctic-, and Iowa-types. However, Flemish-type FAD needs alternative explanation except the aggregation and neurotoxicity of the corresponding A beta 1-42 mutant.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12054732     DOI: 10.1016/S0006-291X(02)00430-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  45 in total

1.  Point mutations in Aβ induce polymorphic aggregates at liquid/solid interfaces.

Authors:  Elizabeth A Yates; Elena M Cucco; Justin Legleiter
Journal:  ACS Chem Neurosci       Date:  2011-04-11       Impact factor: 4.418

2.  Monoclonal antibody against the turn of the 42-residue amyloid β-protein at positions 22 and 23.

Authors:  Kazuma Murakami; Yuko Horikoshi-Sakuraba; Nakaba Murata; Yoshihiro Noda; Yuichi Masuda; Noriaki Kinoshita; Hiroyuki Hatsuta; Shigeo Murayama; Takuji Shirasawa; Takahiko Shimizu; Kazuhiro Irie
Journal:  ACS Chem Neurosci       Date:  2010-09-28       Impact factor: 4.418

3.  Design and Optimization of Anti-amyloid Domain Antibodies Specific for β-Amyloid and Islet Amyloid Polypeptide.

Authors:  Christine C Lee; Mark C Julian; Kathryn E Tiller; Fanling Meng; Sarah E DuConge; Rehana Akter; Daniel P Raleigh; Peter M Tessier
Journal:  J Biol Chem       Date:  2015-11-24       Impact factor: 5.157

4.  Impact of the mutation A21G (Flemish variant) on Alzheimer's beta-amyloid dimers by molecular dynamics simulations.

Authors:  Alexis Huet; Philippe Derreumaux
Journal:  Biophys J       Date:  2006-08-04       Impact factor: 4.033

5.  Similarities in the thermodynamics and kinetics of aggregation of disease-related Abeta(1-40) peptides.

Authors:  Jessica Meinhardt; Gian Gaetano Tartaglia; Amol Pawar; Tony Christopeit; Peter Hortschansky; Volker Schroeckh; Christopher M Dobson; Michele Vendruscolo; Marcus Fändrich
Journal:  Protein Sci       Date:  2007-06       Impact factor: 6.725

Review 6.  Solid-state NMR as a probe of amyloid structure.

Authors:  Robert Tycko
Journal:  Protein Pept Lett       Date:  2006       Impact factor: 1.890

7.  Role of the familial Dutch mutation E22Q in the folding and aggregation of the 15-28 fragment of the Alzheimer amyloid-beta protein.

Authors:  Andrij Baumketner; Mary Griffin Krone; Joan-Emma Shea
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-11       Impact factor: 11.205

8.  Port-to-port delivery: Mobilization of toxic sphingolipids via extracellular vesicles.

Authors:  Giuseppe Scesa; Ana Lis Moyano; Ernesto R Bongarzone; Maria I Givogri
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

9.  Sensitive (13)C- (13)C correlation spectra of amyloid fibrils at very high spinning frequencies and magnetic fields.

Authors:  Markus Weingarth; Yuichi Masuda; K Takegoshi; Geoffrey Bodenhausen; Piotr Tekely
Journal:  J Biomol NMR       Date:  2011-03-29       Impact factor: 2.835

Review 10.  Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

Authors:  Hyunbum Jang; Laura Connelly; Fernando Teran Arce; Srinivasan Ramachandran; Ratnesh Lal; Bruce L Kagan; Ruth Nussinov
Journal:  Phys Chem Chem Phys       Date:  2013-02-28       Impact factor: 3.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.